EVOLUTION AT MERCK - INVENTING FOR LIFE

VACCINES: GROWING GLOBAL BUSINESS WITH NEAR- AND LONG-TERM OPPORTUNITIES ● • • Significant long-term opportunity for pediatric and adult vaccines growth around the world High barriers-to-entry supporting sustained, durable position Investing in vaccines manufacturing capacity to increase doses produced globally Strong pipeline in pneumococcal disease, respiratory syncytial virus (RSV), cytomegalovirus (CMV), dengue and others Nearly doubled vaccines revenue since 2010 $7.3B Other ZOSTAVAX ROTATEQ $5.7B Other PNEUMOVAX 23 ZOSTAVAX ROTATEQ PNEUMOVAX 23 $3.8B Other ZOSTAVAX ROTATEQ PNEUMOVAX 23 PROQUAD-MMR- VARIVAX PROQUAD-MMR- VARIVAX GARDASIL GARDASIL PROQUAD-MMR- VARIVAX GARDASIL 2010 2014 2018 Merck started recording vaccines sales in the 19 European countries previously part of the SPMSD vaccines joint venture starting in January 1, 2017 MERCK Frank Clyburn INVENTING FOR LIFE 24

View entire presentation